Suma Vupputuri1, Teresa M Kimes2, Michael O Calloway3, Jennifer B Christian4, David Bruhn3, Alan A Martin3, Gregory A Nichols2. 1. The Center for Health Research, Kaiser Permanente Georgia, Atlanta, GA. Electronic address: Suma133@hotmail.com. 2. The Center for Health Research, Kaiser Permanente Northwest, Portland, OR. 3. GlaxoSmithKline, US Health Outcomes, Research Triangle Park, NC. 4. GlaxoSmithKline, Clinical Effectiveness & Safety, Research Triangle Park, NC.
Abstract
AIMS: To estimate the rate of progression of chronic kidney disease (CKD) among patients with type 2 diabetes (T2D) and calculate medical costs associated with progression. METHODS: We conducted a retrospective cohort study of 25,576 members at Kaiser Permanente who had T2D and at least one serum creatinine measurement in 2005. Using estimated glomerular filtration rate (eGFR), we assigned patients to baseline stages of kidney function (stage 0-2, >60ml/min/1.73m(2), n=21,008; stage 3, 30-59, n=3,885; stage 4, 15-29, n=683). We examined all subsequent eGFRs through 2010 to assess progression of kidney disease. Medical costs at baseline and incremental costs during follow-up were assessed. RESULTS: Mean age of patients was 60.6years, 51% were men, and mean diabetes duration was 5.3years. At baseline, 17.9% of patients with T2D also had stage 3 or 4 CKD. Incremental adjusted costs that occurred over follow-up (from baseline) was on average $4569, $12,617, and $33,162 per patient per year higher among patients who progressed from baseline stage 0-2, stage 3, and stage 4 CKD, respectively, compared to those who did not progress. Across all stages of CKD, those who progressed to a higher stage of CKD from baseline had follow-up costs that ranged from 2 to 4 times higher than those who did not progress. CONCLUSIONS: Progression of CKD in T2D drives substantial medical care costs. Interventions designed to minimize decline in progressive kidney function, particularly among patients with stage 3 or 4 CKD, may reduce the economic burden of CKD in T2D.
AIMS: To estimate the rate of progression of chronic kidney disease (CKD) among patients with type 2 diabetes (T2D) and calculate medical costs associated with progression. METHODS: We conducted a retrospective cohort study of 25,576 members at Kaiser Permanente who had T2D and at least one serum creatinine measurement in 2005. Using estimated glomerular filtration rate (eGFR), we assigned patients to baseline stages of kidney function (stage 0-2, >60ml/min/1.73m(2), n=21,008; stage 3, 30-59, n=3,885; stage 4, 15-29, n=683). We examined all subsequent eGFRs through 2010 to assess progression of kidney disease. Medical costs at baseline and incremental costs during follow-up were assessed. RESULTS: Mean age of patients was 60.6years, 51% were men, and mean diabetes duration was 5.3years. At baseline, 17.9% of patients with T2D also had stage 3 or 4 CKD. Incremental adjusted costs that occurred over follow-up (from baseline) was on average $4569, $12,617, and $33,162 per patient per year higher among patients who progressed from baseline stage 0-2, stage 3, and stage 4 CKD, respectively, compared to those who did not progress. Across all stages of CKD, those who progressed to a higher stage of CKD from baseline had follow-up costs that ranged from 2 to 4 times higher than those who did not progress. CONCLUSIONS: Progression of CKD in T2D drives substantial medical care costs. Interventions designed to minimize decline in progressive kidney function, particularly among patients with stage 3 or 4 CKD, may reduce the economic burden of CKD in T2D.
Authors: Marc Evans; Angharad R Morgan; Martin B Whyte; Wasim Hanif; Stephen C Bain; Philip A Kalra; Sarah Davies; Umesh Dashora; Zaheer Yousef; Dipesh C Patel; W David Strain Journal: Drugs Date: 2021-12-21 Impact factor: 9.546
Authors: Guozhi Jiang; Andrea O Luk; Claudia H T Tam; Risa Ozaki; Cadmon K P Lim; Elaine Y K Chow; Eric S Lau; Alice P S Kong; Baoqi Fan; Ka Fai Lee; Shing Chung Siu; Grace Hiu; Chiu Chi Tsang; Kam Piu Lau; Jenny Y Leung; Man-wo Tsang; Grace Kam; Ip Tim Lau; June K Li; Vincent T Yeung; Emmy Lau; Stanley Lo; Samuel Fung; Yuk Lun Cheng; Chun Chung Chow; Nelson L S Tang; Yu Huang; Hui-yao Lan; Richard A Oram; Cheuk Chun Szeto; Wing Yee So; Juliana C N Chan; Ronald C W Ma Journal: Diabetes Date: 2022-03-01 Impact factor: 9.461
Authors: Katherine D Westreich; Scott Isom; Jasmin Divers; Ralph D'Agostino; Jean M Lawrence; Roopa Kanakatti Shankar; Lawrence M Dolan; Giuseppina Imperatore; Dana Dabelea; Elizabeth J Mayer-Davis; Amy K Mottl Journal: J Diabetes Complications Date: 2020-10-23 Impact factor: 3.219